(BMRA) Biomerica - Ratings and Ratios

Biomerica, Inc. (NASDAQ:BMRA) is a biomedical technology company specializing in the development, manufacturing, and marketing of diagnostic and therapeutic products. The company focuses on non-invasive tests for gastrointestinal diseases and food intolerances, offering products for physicians, drugstores, and clinical laboratories. Their InFoods IBS uses a blood sample to identify foods that may alleviate IBS symptoms, providing personalized dietary advice. The hp+detect test aids in early detection of H. Pylori infection, a major cause of gastric ulcers. Biomerica also markets COVID-19 diagnostic tests. Founded in 1971, they are headquartered in Irvine, California.

Over the next three months, Biomericas stock is expected to fluctuate between $0.49 and $0.73, influenced by an ATR of $0.12. The stock may find support around $0.59 (SMA50) and resistance at $0.75 (SMA20). With a market cap of $5.46M, the stock is speculative due to the lack of profitability, indicated by a P/E of 0. However, their focus on niche areas and potential partnerships could drive growth. Investors should monitor for news on product approvals or collaborations that might impact stock performance.